{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:00:39Z","timestamp":1792796439081,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013263","name":"Nasjonalforeningen for Folkehelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019902","name":"Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019902","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Long-term adherence to secondary prevention after ischemic stroke remains unclear. This study aimed to evaluate medication adherence, attainment of vascular treatment targets, and clinical characteristics that influence target achievement 3\u2009years post-stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We included 665 home-dwelling ischemic stroke patients from the Norwegian Cognitive Impairment After Stroke study, admitted between May 2015 and March 2017 (n\u2009=\u2009431 were followed for 3\u2009years). Medication adherence was assessed using the 4-item Morisky Medication Adherence Scale, medication persistence, and guideline-based treatment targets: blood pressure (BP)\u2009&amp;lt;\u2009140\/90\u2009mmHg, LDL cholesterol (LDL-C)\u2009&amp;lt;\u20092.0\u2009mmol\/L, and hemoglobin A1c (HbA1c)\u2009\u2a7d\u200953\u2009mmol\/mol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At discharge, prescription rates were 97% for antithrombotics, 67% for antihypertensives, 88% for lipid-lowering drugs (LLD), and 10% for antidiabetics. Three years later, persistence rates were 97%, 91%, 83%, and 94%, respectively, with 73% reporting high medication adherence. Target achievement rates were 42% for BP, 47% for LDL-C, and 75% for HbA1c among diabetic patients. Younger age was associated with better BP control (OR 0.974 per year, 95% CI\u20090.957\u20130.992). Women had poorer LDL-C control (OR 0.55, 95% CI\u20090.33\u20130.91). More LLD (OR 1.25, 95% CI\u20091.14\u20131.37) and higher comorbidity (OR 1.26, 95% CI\u20091.10\u20131.44) were associated with improved LDL-C control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Control of risk factors remained unsatisfactory 3\u2009years after ischemic stroke, despite relatively high persistence and adherence rates. Improved focus on implementing optimal secondary prevention for Norwegian stroke patients is necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/esj\/23969873251329210","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:01:35Z","timestamp":1768906895000},"source":"Crossref","is-referenced-by-count":2,"title":["Three-year adherence to secondary prevention and vascular risk control after ischemic stroke"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6552-7839","authenticated-orcid":false,"given":"Erlend","family":"Fagerli","sequence":"first","affiliation":[{"name":"Department of Circulation and Medical Imaging, NTNU \u2013 Norwegian University of Science and Technology , Trondheim ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Ellekj\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Neuromedicine and Movement Science, NTNU \u2013 Norwegian University of Science and Technology , Trondheim ,","place":["Norway"]},{"name":"Stroke Unit, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital , Trondheim ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olavs Hospital, Trondheim University Hospital , Trondheim ,","place":["Norway"]},{"name":"Department of Clinical and Molecular Medicine, NTNU \u2013 Norwegian University of Science and Technology , Trondheim ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Saltvedt","sequence":"additional","affiliation":[{"name":"Department of Neuromedicine and Movement Science, NTNU \u2013 Norwegian University of Science and Technology , Trondheim ,","place":["Norway"]},{"name":"Department of Geriatric Medicine, St. Olavs Hospital, Trondheim University Hospital , Trondheim ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-7911","authenticated-orcid":false,"given":"Mari Nordb\u00f8","family":"Gynnild","sequence":"additional","affiliation":[{"name":"Department of Circulation and Medical Imaging, NTNU \u2013 Norwegian University of Science and Technology , Trondheim ,","place":["Norway"]},{"name":"Stroke Unit, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital , Trondheim ,","place":["Norway"]},{"name":"Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital , Trondheim ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"2026012115123338000_bibr1-23969873251329210","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","article-title":"Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis","volume":"42","author":"Mohan","year":"2011","journal-title":"Stroke"},{"key":"2026012115123338000_bibr2-23969873251329210","doi-asserted-by":"crossref","first-page":"20180118","DOI":"10.1161\/JAHA.117.007267","article-title":"Long-term risk of myocardial infarction compared to recurrent stroke after transient ischemic attack and ischemic stroke: systematic review and meta-analysis","volume":"7","author":"Boulanger","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012115123338000_bibr3-23969873251329210","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/STROKEAHA.106.475525","article-title":"Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study","volume":"38","author":"Hackam","year":"2007","journal-title":"Stroke"},{"key":"2026012115123338000_bibr4-23969873251329210","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/eurjpc\/zwab050","article-title":"Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: the Troms\u00f8 study 2015-16","volume":"29","author":"Hopstock","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026012115123338000_bibr5-23969873251329210","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1177\/2047487314546825","article-title":"Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey","volume":"22","author":"Heuschmann","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2026012115123338000_bibr6-23969873251329210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12872-016-0387-z","article-title":"Unfavourable risk factor control after coronary events in routine clinical practice","volume":"17","author":"Sverre","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012115123338000_bibr7-23969873251329210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/joim.13161","article-title":"Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke","volume":"289","author":"Gynnild","year":"2021","journal-title":"J Intern Med"},{"key":"2026012115123338000_bibr8-23969873251329210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"2026012115123338000_bibr9-23969873251329210","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/23969873231215629","article-title":"Long-term risk-factor control and secondary prevention are insufficient after first TIA: results from QregPV","volume":"9","author":"Bager","year":"2024","journal-title":"Eur Stroke J"},{"key":"2026012115123338000_bibr10-23969873251329210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12883-018-1198-x","article-title":"The Norwegian cognitive impairment after stroke study (Nor-COAST): study protocol of a multicentre, prospective cohort study","volume":"18","author":"Thingstad","year":"2018","journal-title":"BMC Neurol"},{"key":"2026012115123338000_bibr11-23969873251329210","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jclinepi.2010.09.010","article-title":"Improving the measurement of self-reported medication nonadherence: final response","volume":"64","author":"Morisky","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026012115123338000_bibr12-23969873251329210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence and Long-Term Predictive Validity of Blood Pressure Control","volume":"24","author":"Morisky","year":"1986","journal-title":"Medical Care"},{"key":"2026012115123338000_bibr13-23969873251329210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/109019819001700303","article-title":"A Patient Education Program to Improve Rate with Antituberculosis Drug Regimens","volume":"17","author":"Morisky","year":"1990","journal-title":"Health Education Quarterly"},{"key":"2026012115123338000_bibr14-23969873251329210","article-title":"Norwegian guideline for treatment and rehabilitation in stroke","author":"Helsedirektoratet","year":"2017"},{"key":"2026012115123338000_bibr15-23969873251329210","doi-asserted-by":"crossref","DOI":"10.1177\/23969873221100032","article-title":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack","volume":"7","author":"Dawson","year":"2022","journal-title":"Eur Stroke J"},{"key":"2026012115123338000_bibr16-23969873251329210","doi-asserted-by":"crossref","DOI":"10.1002\/9781118762516","volume-title":"Clinical trials with missing data: a guide for practitioners","author":"O'Kelly","year":"2014"},{"key":"2026012115123338000_bibr17-23969873251329210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/STROKEAHA.109.566950","article-title":"Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke","volume":"41","author":"Glader","year":"2010","journal-title":"Stroke"},{"key":"2026012115123338000_bibr18-23969873251329210","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00415-019-09660-y","article-title":"Post-stroke medication adherence and persistence rates: a meta-analysis of observational studies","volume":"268","author":"Zhang","year":"2021","journal-title":"J Neurol"},{"key":"2026012115123338000_bibr19-23969873251329210","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/gerona\/glx169","article-title":"Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis","volume":"73","author":"Ofori-Asenso","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026012115123338000_bibr20-23969873251329210","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1212\/WNL.0b013e31822f0423","article-title":"Secondary preventive medication persistence and adherence 1 year after stroke","volume":"77","author":"Bushnell","year":"2011","journal-title":"Neurology"},{"key":"2026012115123338000_bibr21-23969873251329210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12875-015-0221-1","article-title":"Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium","volume":"16","author":"Aujoulat","year":"2015","journal-title":"BMC Fam Pract"},{"key":"2026012115123338000_bibr22-23969873251329210","doi-asserted-by":"crossref","first-page":"633","DOI":"10.21037\/cdt.2017.04.06","article-title":"The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention","volume":"7","author":"Kotseva","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026012115123338000_bibr23-23969873251329210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12875-018-0872-9","article-title":"Stroke follow-up in primary care: a prospective cohort study on guideline adherence","volume":"19","author":"Pedersen","year":"2018","journal-title":"BMC Fam Pract"},{"key":"2026012115123338000_bibr24-23969873251329210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bmjqs-2022-015699","article-title":"Comparing secondary prevention for patients with coronary heart disease and stroke attending Australian general practices: a cross-sectional study using nationwide electronic database","volume":"33","author":"Yue","year":"2024","journal-title":"BMJ Qual Saf"},{"key":"2026012115123338000_bibr25-23969873251329210","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"2026012115123338000_bibr26-23969873251329210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1161\/STROKEAHA.124.048058","article-title":"Sex differences in prescription patterns and medication adherence to guideline-directed medical therapy among patients with ischemic stroke","volume":"56","author":"Mansoor","year":"2025","journal-title":"Stroke"},{"key":"2026012115123338000_bibr27-23969873251329210","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-001972","article-title":"Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment","volume":"9","author":"Gynnild","year":"2022","journal-title":"Open Heart"},{"key":"2026012115123338000_bibr28-23969873251329210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12889-020-09165-8","article-title":"Prevalence, awareness, treatment, and control of hypertension in older people: results from the population-based KORA-age 1 study","volume":"20","author":"Muli","year":"2020","journal-title":"BMC Public Health"},{"key":"2026012115123338000_bibr29-23969873251329210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ajh\/hpab002","article-title":"Blood pressure control among older adults with hypertension: narrative review and introduction of a framework for improving care","volume":"34","author":"Bowling","year":"2021","journal-title":"Am J Hypertens"},{"key":"2026012115123338000_bibr30-23969873251329210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12872-021-01866-1","article-title":"Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Troms\u00f8 7","volume":"21","author":"Pedersen","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012115123338000_bibr31-23969873251329210","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"2026012115123338000_bibr32-23969873251329210","article-title":"Norwegian Stroke Registry: Annual report 2023","author":"Skogseth-Stephani"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/1\/23969873251329210\/66196004\/23969873251329210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/1\/23969873251329210\/66196004\/23969873251329210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:16:57Z","timestamp":1769026617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/doi\/10.1093\/esj\/23969873251329210\/8407722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/esj\/23969873251329210","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1,1]]},"article-number":"23969873251329210"}}